About Us
Our founding team combines talented and accomplished scientists with a wealth of experience in the stem cells and diabetes field, with a strong business and commercialization team. Together, we are committed to translating stem cell technologies into therapeutic applications.
Our goal is to develop high quality, stem cell-based regenerative therapeutic solutions for diabetes. Our core technology was developed at the Agency for Science, Technology and Research (A*STAR) in Singapore.
We run our very own state-of-the-art laboratory facility with both R&D and cell manufacturing capabilities, in the heart of Singapore.
Our Leadership Team
Clinical Advisors
Dr. Koh Ye Xin
Scientific Operations
Resilind Chew
Zainab Yasin
Lim Kah Meng, PhD
Managing Director
Dr Lim Kah Meng has dedicated a large part of his research focus to molecular biomedicine and has a track record of turning early-stage technologies into successful entrepreneurial endeavours. For more than 20 years, he fervently pursued his scientific interests in bioactive molecules that govern and regulate cellular pathways leading to cellular homeostasis and well-being. Being credited as the “Father of Molecular Edible Bird’s Nest”, Dr Lim has filed multiple patents on the extraction processes for bioactive molecules including immunologically active biomolecules from edible bird nests.
Dr Lim is also known in this region to be the “Father of Molecular Placenta” where he has successfully developed highly popular products for the commercial world based on placental stem cell extracts.
He has since diversified into stem cell research including products or platforms based on induced pluripotent stem cells for therapeutic applications for illnesses such as diabetes, psoriasis and dementia.
On biologics research, Dr Lim has at least a few years of previous experience working with leading global biologics experts both at the Agency for Science, Technology and Research (A*STAR) [Singapore] as well as at the University of Minnesota [USA].
Dr Lim is also deep into biomedical research for neuroscience. He has filed for at least 5 patents related to cannabinoids, specifically on medical cannabis but not exclusive to just neurological functions. Dr Lim’s most recent work is in successfully using microRNAs as next-generation diagnostic markers for most cancer and chronic diseases detection. Dr Lim was also the recipient of the Singapore Award of the 10 Outstanding Young Persons of the World in 2012.
Dr Lim joined Singapore PainCare Holdings Ltd as an independent Non-Executive Director in March 2021 and at the same time, serves as an Honorary Advisor of the World LIN Chamber of Commerce, Singapore.
Dr Adrian Teo
Scientific Co-Founder & Advisor
Dr Adrian Teo obtained his B.Sc. (1st Class) from the National University of Singapore. He completed his PhD in stem cell biology with Ludovic Vallier at the University of Cambridge, under an A*STAR Scholarship. Concurrently, he was also an Honorary Cambridge Commonwealth Trust Scholar. He then trained with Rohit Kulkarni at Joslin Diabetes Center, Harvard Medical School, as a Juvenile Diabetes Research Foundation fellow, on pancreatic islet biology and diabetes.
Adrian is currently a Principal Investigator at the Institute of Molecular and Cell Biology (IMCB), A*STAR, and an Assistant Professor at NUS Medicine, Singapore, using human pluripotent stem cells for disease modelling of diabetes. He is a recipient of the Interstellar Initiative awards, Dr Susan Lim Award for Outstanding Young Investigator 2018, the JCI Ten Outstanding Young Persons (TOYP) of Singapore Honoree Award 2019 on Medical Innovation and Graduate Mentor of the Year Award 2022. He is a member of the Oxbridge Society of Singapore, the International Society for Stem Cell Research and an EXCO member/Vice-Treasurer of the Stem Cell Society Singapore.
LinkedIn: http://linkedin.com/in/adrian-teo-12061b6
Twitter: @Drainteo
Dr Natasha Ng
Scientific Co-Founder & Advisor
Dr Natasha Ng is a Senior Research Fellow at the Institute of Molecular and Cell Biology (IMCB), A*STAR, in the Stem Cells and Diabetes Lab (Adrian Teo Lab). Her research work seeks to understand the genetic and molecular mechanisms underlying the development of diabetes using stem cell technologies, to uncover new therapeutic pathways for tackling the disease. She has over ten years of experience in diabetes research and over six years of experience in induced pluripotent stem cell technologies.
Natasha previously graduated with a B.Sc. (First Class Honours) in Biology at Imperial College London, followed by a D.Phil. in Medical Sciences at the University of Oxford in 2016 under the supervision of Prof Anna Gloyn and Prof Patrick Rorsman. Since 2014 she has also been a co-founder of BioMe Oxford, a UK-based, medical device start-up developing a targeted gastrointestinal sampling device. The company is undergoing joint development work and early-phase human trials with the microbiome venture arm of International Flavors & Fragrances (IFF). Natasha is also an Advisor of Biotech Connection Singapore (BCS), after having served as previous Consulting Lead and President in the organisation, a member of the International Society for Cell & Gene Therapy (ISCT) Asia Regional Early Stage Professionals (ESP) Subcommittee, as well as an ExCo member of Stem Cell Society Singapore.